Group 1: Market Overview - The National Medical Insurance Administration is advancing the "going out" strategy for Chinese pharmaceuticals and medical devices, with a focus on building a multi-level support network for international procurement by 2026[1] - In 2025, China is expected to approve 76 innovative drugs, with over 150 transactions amounting to more than $130 billion[1] - By 2024, China's medical device exports are projected to account for 8.17% of the global market, maintaining the fourth position worldwide[1] Group 2: Financial Performance - Revenue for medical device manufacturing companies in China is expected to reach 1.42 trillion yuan in 2025, reflecting a year-on-year growth of 5%[1] - As of October 2025, the number of medical device manufacturers in China reached 33,300, an increase of 576 from the end of 2024[1] - The number of effective invention patents in the medical device sector is projected to reach 50,525 by 2024, a year-on-year increase of 21.63%[1] Group 3: Export and Import Trends - From January to October 2025, the export value of IVD instruments, diagnostic equipment, and dental materials was 30.8 billion yuan, 67.4 billion yuan, and 9.3 billion yuan respectively, with year-on-year growth rates of 11.16%, 9.43%, and 12.15%[1] - IVD reagent imports saw a year-on-year decline of 22.89%, indicating reduced reliance on imports, while high-end diagnostic equipment still shows demand[1] Group 4: Stock Market Performance - The North Exchange's pharmaceutical and biological sector saw a weekly increase of 1.18%, with medical devices rising by 1.83%[2] - 85.71% of pharmaceutical and biological stocks on the North Exchange experienced price increases this week[2]

东莞证券股份有限公司 关于四川千里倍益康医疗科技股份有限公司 2025 年度持续督导定期现场检查报告 东莞证券股份有限公司（以下简称"东莞证券"或"保荐机构"）作为四川 千里倍益康医疗科技股份有限公司（以下简称"倍益康"或"公司"）向不特定 合格投资者公开发行股票并在北京证券交易所上市的保荐机构，负责公司的持续 督导工作。根据《证券发行上市保荐业务管理办法》《北京证券交易所股票上市 规则》《北京证券交易所上市公司持续监管指引第 14 号——保荐机构持续督导》 等有关法律法规、规范性文件的规定，对公司进行 2025 年度定期现场核查并出 具核查报告。具体情况如下： | 保荐人名称：东莞证券股份有限公司 上市公司简称：倍益康 | | | | | --- | --- | --- | --- | | 保荐代表人姓名：叶双红、袁炜 | | | | | 现场检查人员姓名：叶双红 | | | | | 现场检查对应期间：2025年度 | | | | | 现场检查时间：2025年12月31日 | | | | | 一、现场检查事项 | | 现场检查意见 | | | （一）公司治理 | 是 | 否 | 不适用 | | 现场检查手段 ...

证券代码：920199 证券简称：倍益康 公告编号：2026-005 四川千里倍益康医疗科技股份有限公司股票解除限售公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、本次股票解除限售数量总额为 967,680 股，占公司总股本 1.4208%，可交易 时间为 2026 年 1 月 27 日。 单位：股 注：解除限售原因： A 董事、高级管理人员每年解除限售 B 离任董事、监事、高级管理人员解除限售 C 自愿限售解除限售 D 限制性股票解除限售 | 序号 | 股东姓名 或名称 | 是否为控 股股东、 实际控制 | | 本次解限 售原因 | 本次解除 | 本次解 除限售 股数占 公司总 | 尚未解除 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 任职情况 | | 限售登记 | | 限售的股 | | | | 人或其一 | | | 股票数量 | | 票数量 | | | | 致行动人 | | | | 股本比 | | | | | | ...

公司严格遵守各项制度要求，根据募集资金用途使用募集资金。截至 2025 年 12 月 31 日，公司募集资金的存储情况如下： 关于四川千里倍益康医疗科技股份有限公司 1 东莞证券股份有限公司 募投项目结项并将节余募集资金永久补充流动资金的核查意见 东莞证券股份有限公司（以下简称"东莞证券"或"保荐机构"）作为四川 千里倍益康医疗科技股份有限公司（以下简称"倍益康"或"公司"）向不特定 合格投资者公开发行股票并在北交所上市的保荐机构，根据《北京证券交易所上 市公司持续监管办法（试行）》《北京证券交易所证券发行上市保荐业务管理细 则》《北京证券交易所股票上市规则》《北京证券交易所上市公司持续监管指引 第 9 号——募集资金管理》等有关规定，对公司募投项目结项并将节余募集资金 永久补充流动资金事项进行了审慎核查，具体情况如下： 一、募集资金基本情况 倍益康于 2022 年 11 月 3 日收到中国证券监督管理委员会下发的《关于同意 四川千里倍益康医疗科技股份有限公司向不特定合格投资者公开发行股票注册 的批复》（证监许可〔2022〕2681 号），同意公司向不特定合格投资者公开发行 股票的注册申请。公司本次发行的发行 ...

证券代码：920199 证券简称：倍益康 公告编号：2026-003 四川千里倍益康医疗科技股份有限公司 关于部分募投项目结项并将节余募集资金永久补充流动资金的公告 注：以上账户余额包括银行存款利息收入。 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 鉴于四川千里倍益康医疗科技股份有限公司（以下简称"公司"）2022 年向 不特定合格投资者公开发行股票募集资金投资项目之"研发中心升级建设项目" 与"营销网络及品牌宣传建设项目"（以下简称"募投项目"）已建设完毕，达到 预定可使用状态，公司拟将上述募投项目予以结项，并将结项后的节余募集资金 用于永久补充流动资金。具体情况公告如下： 一、募集资金基本情况 公司于 2022 年 11 月 3 日收到中国证券监督管理委员会下发的《关于同意四 川千里倍益康医疗科技股份有限公司向不特定合格投资者公开发行股票注册的 批复》（证监许可〔2022〕2681 号），同意公司向不特定合格投资者公开发行股票 的注册申请。公司本次发行的发行价格为31.80元/股，发行股数为11 ...

√是 □否 证券代码：920199 证券简称：倍益康 公告编号：2026-002 四川千里倍益康医疗科技股份有限公司 股东拟减持股份的预披露公告 本公司及董事会全体成员及相关股东保证公告内容不存在虚假记载、误导性 陈述或重大遗漏，并对其内容的真实、准确和完整承担个别及连带责任。 | 股东名称 | 股东身份 | 持股数量 | 持股比例 | 当前持股股份来源 | | --- | --- | --- | --- | --- | | 成都市千 | | （股） | （%） | | | 里致远企 | | | | | | 业管理中 | 员工持股平台 | | | 上市前取得（含权益 | | | | 7,836,244 | 11.51% | 分派转增股） | | 心（有限合 | | | | | | 伙） | | | | | | 成都市千 | | | | | | 里志达企 | | | | 上市前取得（含权益 | | 业管理中 | 员工持股平台 | 1,355,150 | 1.99% | 分派转增股） | | 心（有限合 | | | | | | 伙） | | | | | | | 实际控制人、 | | | 上市前取得（含权益 | | ...

Group 1 - The report highlights the launch of "ChatGPT Health" by OpenAI, which integrates health-related conversations and connects to electronic medical records, indicating a significant potential market for AI in healthcare [9][12] - The "Artificial Intelligence + Manufacturing" initiative aims to achieve reliable supply of core AI technologies and maintain a leading position in the industry by 2027, with specific targets including the application of 3-5 general large models in manufacturing and the creation of 100 high-quality industrial datasets [12][14] - The report identifies key sectors such as AI healthcare, AI pharmaceuticals, and AI biomanufacturing as focal points for development, proposing measures like building intelligent drug discovery platforms and smart supply chain management systems [16][12] Group 2 - The North Exchange's biopharmaceutical sector saw a weekly increase of 5.85%, with medical devices rising by 7.81%, indicating strong market performance [23][26] - Among the biopharmaceutical companies, 90.48% experienced stock price increases, with notable performers including BeiYikang (+45.1%) and XinGanjian (+10.46%) [33][34] - As of January 9, 2026, there are 15 companies in the biopharmaceutical sector awaiting approval on the North Exchange, with an average projected revenue of 424 million yuan for 2024 [34][38] Group 3 - The report emphasizes the importance of AI in enhancing drug development efficiency and supply chain management, aiming to reduce costs and time in pharmaceutical processes [16][12] - The global AI healthcare market is projected to reach approximately $26.65 billion in 2024, with a compound annual growth rate (CAGR) of 38.8% expected until 2033 [18][17] - The Chinese AI healthcare industry is expected to grow from 97.3 billion yuan in 2023 to 159.8 billion yuan by 2028, reflecting significant growth potential in this sector [18][19]

Group 1 - The North Exchange 50 index increased by 5.82%, with average daily trading volume rising by 34.58% [4][12] - The strongest sectors this week included military, TMT, and pharmaceuticals, with the commercial aerospace sector showing significant strength [7][8] - Notable stock performances included Tianli Composite (+35.97%), Huitong New Materials (+23.77%), and Beikang (+45.1%) [4][7] Group 2 - The North Exchange's strong stock ratio increased to 38.7%, indicating potential for continued market momentum [7][11] - The report highlights a shift in market style from small-cap stocks to growth sectors, particularly in AI computing and other emerging technologies [7][8] - The report emphasizes the importance of timing in thematic investments, particularly in the context of the upcoming "14th Five-Year Plan" [7][8] Group 3 - The report identifies key sectors to watch in the upcoming week, including the space photovoltaic industry and AI applications [8] - Specific companies of interest include Liancheng Numerical Control, Optech, and Deepseek V4, among others [8] - The report anticipates a return of absolute return funds in early 2026, with a focus on undervalued stocks [8] Group 4 - The North Exchange had 287 companies listed as of January 9, 2026, with new listings and approvals ongoing [24][28] - This week, five new companies were listed, and five were delisted, with a total planned financing of 221 million yuan [42][44] - The report notes that the North Exchange's PE (TTM) median is 42.05 times, reflecting a positive trend in valuations [12][19]

Market Performance - The North Exchange 50 Index increased by 5.82% compared to the previous week, while the Shanghai and Shenzhen 300 Index rose by 2.79% and the ChiNext Index by 3.89%[30] - The average market capitalization of North Exchange A-shares reached 3.197 billion yuan, with a daily average trading volume of approximately 26.13 billion yuan, up 34.57% from the previous week[5] Investment Recommendations - Focus on sectors with high industry prosperity and scarcity, particularly commercial aerospace, robotics, low-altitude economy, energy storage, solid-state batteries, and liquid cooling[40] - The PE ratios for North Exchange A-shares, ChiNext, Shanghai Main Board, Shenzhen Main Board, and Sci-Tech Innovation Board are 48.40, 45.54, 12.69, 24.07, and 78.26 respectively as of January 9, 2026[40] Economic Indicators - The Consumer Price Index (CPI) rose by 0.8% year-on-year in December 2025, marking the highest increase since March 2023[22] - The Producer Price Index (PPI) increased by 0.2% month-on-month in December 2025, but decreased by 1.9% year-on-year[22] Regulatory Developments - The People's Bank of China is expected to implement a prudent monetary policy, emphasizing the need for financial support for economic stability and growth in 2026[11] - The China Securities Regulatory Commission is intensifying efforts to combat financial fraud in the capital market, with 159 cases of financial fraud handled in 2024[18] Industry News - China applied for frequency resources for over 200,000 satellites in December 2025, indicating a significant expansion in the commercial aerospace sector[29] - The United Nations projects global economic growth at 2.7% for 2026, slightly lower than the 2.8% estimated for 2025, amid ongoing macroeconomic uncertainties[26]

Summary of Key Points Core Viewpoint - The trading volume and value of stocks on the Beijing Stock Exchange (BSE) saw a significant increase on January 9, with a total trading volume of 1.14 billion shares and a trading value of 29.886 billion yuan, marking an increase of 3.682 billion yuan compared to the previous trading day [1]. Trading Performance - A total of 202 stocks closed higher, representing 70.38% of the tradable stocks on the BSE, with notable gainers including Ge Li Er and Zhong Cheng Technology, which hit the daily limit up [1]. - The top gainers included Fuji Da, Hai Neng Technology, and Xing Tu Ce Kong, with increases of 9.47%, 7.95%, and 7.81% respectively [1]. - Conversely, 77 stocks closed lower, with Bei Yi Kang, Kai De Quartz, and Tian Li Composite showing the largest declines of 11.47%, 7.23%, and 6.18% respectively [1]. Trading Activity - There were 84 stocks with a trading value exceeding 10 million yuan, with Tian Li Composite, Fuji Da, and Xing Tu Ce Kong leading in trading value at 1.128 billion yuan, 1.051 billion yuan, and 1.037 billion yuan respectively [1]. - The trading activity was robust, with 44 stocks having a turnover rate exceeding 10%, and 10 stocks exceeding 20% [1]. Notable Stocks - The stock with the highest turnover rate was Zhong Cheng Technology at 35.49%, followed by Tian Run Technology at 28.04% and Da Peng Industrial at 27.70% [1]. - The trading details of several notable stocks were provided, highlighting their closing prices, percentage changes, turnover rates, and trading values [1][2][3][4][5][6][7][8][9][10].